SubsidieMeestersLectibodies to Eliminate Tumours
This project aims to develop lectibodies for targeted delivery of therapeutics to neuroblastoma by harnessing GSL-binding proteins, potentially revolutionizing cancer treatment.
Projectdetails
Introduction
Antibody-mediated delivery of therapeutic compounds to tumor cells for the treatment of cancer is a rapidly growing multibillion-euro market. One class of tumor markers, the glycosphingolipids (GSLs), are only rarely addressed in this context, due to the difficulty of obtaining antibodies against them.
Project Overview
In this proof-of-concept program, we will develop a novel class of products — lectibodies — for the delivery of therapeutic compounds to tumor-specific GSLs. Our lectibodies are based on a naturally occurring GSL-binding protein with intrinsic tumor targeting capacity.
Technology Development
We will rely on a proprietary phage library technology to isolate lectibodies against GSLs (or cocktails thereof). In this PoC program, we will optimize and apply our technology to specifically target O-acetyl GD2, a GSL highly expressed in neuroblastoma tissues.
Market Potential
This will enable us to generate lectibody-based therapeutics against neuroblastoma in children, a devastating disease for which the drug market is predicted to reach €118 million in 2022.
Business Development Options
We will explore two options for further business development:
- Building off of our current partnership with OGD2 Pharma (a biotech based in Nantes, France).
- Creation of a spin-off company which will license deals to several pharmaceutical partners based on pathology.
Expertise and Collaboration
We will capitalize on the expertise in launching start-ups of our principal investigator and on close links with clinicians and industry partners.
Future Applications
Our technology has truly groundbreaking potential as, in principle, chimeric lectibodies can be developed against virtually any tumor-specific cocktail of GSLs, thus opening the door for the development of novel therapies for several cancers.
Following the development of neuroblastoma-specific lectibodies, we foresee a wider range of future applications for our technology.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 30-11-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEpenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Bispecific bi-paratopic antibodies for the treatment of cancerThis project aims to develop novel bispecific antibodies to enhance immune response in NSCLC by targeting dual epitopes, potentially improving treatment outcomes for resistant cancer patients. | ERC Proof of... | € 150.000 | 2025 | Details |
Novel therapeutic platform for aggressive lymphoma: NanoLymphomaNanoLymphoma aims to develop a novel therapeutic platform using nanofilaments to cluster multiple lymphoma targets, enhancing tumor cell death and providing a promising treatment for aggressive B-cell lymphoma. | ERC Proof of... | € 150.000 | 2023 | Details |
Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma ImmunotherapyGLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity. | ERC Starting... | € 1.498.175 | 2025 | Details |
Development of an immune-armed therapeutic adenoviral platform for pediatric brain tumorsThe POPCORN project aims to develop an innovative oncolytic virus platform that enhances anti-tumor immune responses for treating aggressive pediatric brain tumors, improving survival rates and quality of life. | ERC Proof of... | € 150.000 | 2025 | Details |
Preclinical validation and market analysis of a microMESH implant for brain cancer eradicationThe project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes. | ERC Proof of... | € 150.000 | 2022 | Details |
Bispecific bi-paratopic antibodies for the treatment of cancer
This project aims to develop novel bispecific antibodies to enhance immune response in NSCLC by targeting dual epitopes, potentially improving treatment outcomes for resistant cancer patients.
Novel therapeutic platform for aggressive lymphoma: NanoLymphoma
NanoLymphoma aims to develop a novel therapeutic platform using nanofilaments to cluster multiple lymphoma targets, enhancing tumor cell death and providing a promising treatment for aggressive B-cell lymphoma.
Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma Immunotherapy
GLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity.
Development of an immune-armed therapeutic adenoviral platform for pediatric brain tumors
The POPCORN project aims to develop an innovative oncolytic virus platform that enhances anti-tumor immune responses for treating aggressive pediatric brain tumors, improving survival rates and quality of life.
Preclinical validation and market analysis of a microMESH implant for brain cancer eradication
The project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Precision control of glycosylation to open a new era of therapeutic antibodiesGlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments. | EIC Transition | € 2.499.540 | 2025 | Details |
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance. | EIC Transition | € 1.881.875 | 2023 | Details |
Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELiminationSCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy. | EIC Pathfinder | € 4.554.301 | 2025 | Details |
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Precision control of glycosylation to open a new era of therapeutic antibodies
GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.
Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELimination
SCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy.
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)
NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models.
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.
GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes.